Ranibizumab for Macular Edema Secondary to Central and Branch Retinal Vein Occlusion in Patients Younger Than 50 Years of Age.
Maurizio Battaglia ParodiFrancesco RomanoAlessandro ArrigoStefano MercuriAlessandro FranceschiFrancesco Maria BandelloPublished in: BioMed research international (2020)
Our study indicates that IVR injections can be a valid therapeutic option in patients under 50 years of age with ME secondary to RVO.